Skip to Main Content

++

INTRODUCTION

++

laronidase (la-ron-i-dase)

Aldurazyme

Classification

Therapeutic: replacement enzymes

Pharmacologic: enzymes

++
Indications
++

Mucopolysaccharidosis I (MPS I; specifically Hurler and Hurler-Scheie form or Scheie form) with moderate to severe symptoms.

++
Action
++

Replaces the naturally occurring enzyme α-L-iduronidase which is deficient in MPS I. Without replacement, the glucosaminoglycans dermatan and heparan accumulate in tissues. Therapeutic Effects: Decreased cellular, tissue, and organ damage due to MPS accumulation resulting in improved pulmonary function and walking capacity.

++
Adverse Reactions/Side Effects
++

Resp: respiratory tract infections. Derm: rash. Local: injection site reactions. Misc: ALLERGIC REACTIONS, INCLUDING ANAPHYLAXIS, infusion-related reactions.

++

PHYSICAL THERAPY IMPLICATIONS

++
Examination and Evaluation
++

  • Monitor signs of allergic reactions and anaphylaxis, including pulmonary symptoms (tightness in the throat and chest, wheezing, cough, dyspnea) or skin reactions (rash, pruritus, urticaria). Be especially alert for allergy-like responses that occur during and after administration (infusion-related reactions). Notify physician immediately if these reactions occur.

  • Assess ambulation on level surfaces and during stair climbing. Document any changes in functional ability to help determine if drug therapy is effective in maintaining or improving motor function.

  • Assess for signs of respiratory tract infections such as fever, cough, sputum production, shortness of breath, difficulty breathing, and fatigue. Notify physician if these signs occur.

  • Monitor IV infusion site for pain, swelling, and irritation. Report prolonged or excessive infusion-site reactions to the physician.

++
Interventions
++

  • Implement therapeutic exercises (resistive training, coordination exercises, gait training) to complement the effects of drug therapy and help achieve optimal function.

++
Pharmacokinetics
++

Absorption: IV administration results in complete bioavailability.

++

Distribution: Unknown.

++

Metabolism and Excretion: Unknown.

++

Half-life: 1.5–3.6 hr.

++

Table Graphic Jump Location
Favorite Table | Download (.pdf) | Print

TIME/ACTION PROFILE

ROUTE ONSET PEAK DURATION
IV unknown unknown 1 wk

++
Contraindications/Precautions
++

Contraindicated in: None known.

++

Use Cautiously in: Pregnancy (use only if clearly needed); Lactation (safety not established).

++
Interactions
++

Drug-Drug: None known.

++
Route/Dosage
++

IV (Adults and Children): 0.58 mg/kg once weekly, pretreat with antipyretics and/or antihistamines.

++
Availability
++

Solution for injection: 2.9 mg/5 mL-vial.

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.